HER2 Exon 20 Mutation Active Not Recruiting Phase 3 Trials for Pyrotinib (DB14993)

Also known as: HER2 Exon 20 Mutations

IndicationStatusPhase
DBCOND0130258 (HER2 Exon 20 Mutation)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04447118Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyTreatment